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Abstract
Urokinase plasminogen activator receptor (uPAR) is a multidomain protein that plays important roles in the growth,
invasion, and metastasis of a number of cancers. In the present study, we examined the effects of administration of
a monoclonal anti-uPAR antibody (ATN-658) on prostate cancer progression in vitro and in vivo. We examined the
effect of treatment of ATN-658 on human prostate cancer cell invasion, migration, proliferation, and regulation of in-
tracellular signaling pathways. For in vivo studies, PC-3 cells (1 × 106) were inoculated into the right flank of male
Balb C nu/nu mice through subcutaneous or through intratibial route (2 × 105) of male Fox Chase severe combined
immunodeficient mice to monitor the effect on tumor growth and skeletal metastasis. Treatment with ATN-658 re-
sulted in a significant dose-dependent decrease in PC-3 cell invasion and migration without affecting cell doubling
time. Western blot analysis showed that ATN-658 treatment decreased the phosphorylation of serine/threonine pro-
tein kinase B (AKT), mitogen-activated protein kinase (MAPK), and focal adhesion kinase (FAK) without affecting AKT,
MAPK, and FAK total protein expression. In in vivo studies, ATN-658 caused a significant decrease in tumor volume
and a marked reduction in skeletal lesions as determined by Faxitron x-ray and micro–computed tomography. Immu-
nohistochemical analysis of subcutaneous and tibial tumors showed a marked decrease in the levels of expression of
pAKT, pMAPK, and pFAK, consistent with the in vitro observations. Results from these studies provide compelling
evidence for the continued development of ATN-658 as a potential therapeutic agent for the treatment of prostate and
other cancers expressing uPAR.
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Introduction
Overexpression of the urokinase plasminogen activator receptor (uPAR)
has been demonstrated in several different cell types found in tumors,
including the tumor cells themselves, angiogenic endothelial cells, and
tumor-infiltrating inflammatory cells but rarely in normal tissue [1–3].
uPAR expression has been detected in numerous solid tumor types, includ-
ing prostate cancer, where uPAR expression has been demonstrated to be
associated with high-risk disease and to have a prognostic role [4,5]. uPAR
is involved in numerous activities associated with tumor progression, in-
cluding tumor cell proliferation and survival, migration and invasion, an-
giogenesis, and metastasis [6–9] and, as such, represents a well-validated
therapeutic target for the treatment of cancer. However, despite copious
amounts of data supporting the therapeutic targeting of this receptor,
there are currently no uPAR-targeted therapeutics in human clinical trials.
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Historically, attempts at targeting uPAR have focused on attenuat-
ing cell surface proteolysis by inhibiting the binding of the zymogen
form of urokinase plasminogen activator (single-chain uPA [scuPA]),
long considered the main ligand for uPAR, to the cell surface, which
decreases the catalytic efficiency of scuPA activation by several hundred
fold [10]. These approaches have experienced a number of problems
and, when tested in animal tumor models, have exhibited modest activ-
ity at best [11,12], leading to the current paucity of therapeutic agents
targeting uPAR in the clinic.
Effects of uPAR are mediated through the activation of key intra-
cellular signaling pathways. A number of extracellular epitopes that
interact with these signaling mediators are located within domains 2
and 3 (D2 and D3) of uPAR. In recent years, it has become apparent
that uPAR has multiple ligands in addition to uPA. Many of these
ligands (integrins, extracellular matrix components, and growth factor
receptors) have independently been identified as being important to
tumor progression [13–15], suggesting that targeting some of these
other interactions of uPAR may also have therapeutic utility. In addi-
tion, genetic knockdown approaches in several studies demonstrated that
decreasing uPAR expression had profound effects on tumor growth, in
contrast to what had been observed with approaches targeting uPA bind-
ing [16,17]. These results led to the hypothesis that interfering with the
interaction of uPAR with one or more of its other, non-uPA ligands
might lead to a more robust antitumor effect. To address this hypothesis,
a uPAR fragment-based immunization approach was used to generate
a panel of anti-uPAR monoclonal antibodies with the idea of identify-
ing clones that did not block the binding of uPA to uPAR but would
bind to other epitopes on uPAR that might be important to some of
the other biologic functions of this receptor. One such antibody, ATN-
658, a mouse IgG1, is able to bind to D2D3 of uPAR with high affinity
(K d ∼ 1 nM), does not inhibit the binding of uPA to uPAR, and is able
to bind to uPAR even when uPA was also bound. ATN-658 inhibits
invasion, migration, and, in some cell types, proliferation [18]. Thus,
ATN-658 may exemplify a new paradigm for the targeting of uPAR.
Because of the association of uPAR with high-risk disease and prog-
nosis in patients with prostate cancer, ATN-658 was evaluated in this
study for its ability to inhibit the growth of both primary and metas-
tatic prostate cancer tumors using the PC-3 human prostate adeno-
carcinoma cell line.
Materials and Methods
Cell Culture and Treatment
Human prostate cancer cell line PC-3 and the cervical carcinoma
cell line HeLa were obtained from the American Type Culture Collec-
tion (Manassas, VA). Cells were maintained in RPMI 1640 medium
(Invitrogen Life Technologies, Burlington, Ontario, Canada) with 2 mM
L-glutamine, 10% FBS, and 100 U/ml of penicillin-streptomycin sul-
fate. Cells were incubated at 37°C in 5% CO2.
Antibodies
The anti–mitogen-activated protein kinase (MAPK) antibody (ERK1,
catalog no. SC-94, rabbit IgG) was purchased from Santa Cruz Biotech-
nologies (Santa Cruz, CA). The anti–phosphorylated MAPK antibody
(clone 20G11, catalog no. 4376, rabbit IgG) and anti–phosphorylated
serine/threonine protein kinase B (AKT) antibody (pAKT, catalog no.
3787, rabbit IgG) were purchased from Cell Signaling (Danvers, MA);
anti-AKT antibody (catalog no. Ab8805, rabbit IgG) was purchased
from Abcam (Cambridge, MA); anti–phosphorylated FAK antibody
(pFAK, catalog no. 44-624G, rabbit IgG) was purchased from
Biosource (Camarillo, CA); anti–focal adhesion kinase (FAK) antibody
(catalog no. 1700-1, rabbit IgG) was purchased from Epitomics (Bur-
lingame, CA). The mouse and rabbit IgG isotype control antibodies
were purchased from Dako (Carpinteria, CA). These antibodies were
validated at Mosaic Laboratories (Lake Forest, CA) for use in detecting
their respective antigens and were used as described in Immunohisto-
chemical Analyses. ATN-658, which does not block the binding of
uPA to uPAR, and ATN-617, which does block binding of uPA to
uPAR, were raised against D2D3 of uPAR as previously described [18].
Cell Binding Assays
scuPA was radiolabeled using iodine I 125 (125I), and competition
binding assays were carried out as previously described [19]. The bind-
ing and wash buffer for the binding assays was Hank’s balanced salt
solution 0.1% BSA. Briefly, HeLa cells were seeded into 24-well plates
(150,000 cells per well) and allowed to adhere for 24 hours before
use. For the competition studies, medium was aspirated, and 500 μl
of either ATN-617 or ATN-658 at different concentrations was added
to the wells followed by 125I-scuPA (0.2 nM; 20,000 cpm/well). The
plates were incubated for 1 hour at room temperature followed by as-
piration of the binding buffer and washing of the cells (3× with 0.5 ml
of wash buffer). The cells were then lysed, the lysates were transferred to
tubes, and the amount of 125I-scuPA in each well was measured using
a gamma counter.
The direct binding of ATN-658 was measured as follows. ATN-658
was biotinylated using a commercially available kit (EZ-link sulfo-
NHS-LC-biotin; Pierce Chemical, Rockford, IL) as per the manufac-
turer’s instructions. Biotin–ATN-658 bound with similar affinity to
nonbiotinylated ATN-658 was measured in a competition study using
HeLa cells (data not shown). PC-3 cells (50,000 cells per well in
96-well plates) were plated and allowed to adhere overnight in culture
medium with 10% FBS. Biotin-ATN-658 was diluted in PBS with
0.1% casein at different concentrations of antibody. Cells were washed
(3×) with PBS with 0.05% Tween-20, and different concentrations of
biotin–ATN-658 were added and incubated for 1 hour at 37°C. Cells
were washed again (5×) using PBS with 0.05% Tween-20 and OPD
substrate (200 μl per well) was added and incubated for 15 minutes at
room temperature in the dark. The reaction was quenched using 1 M
H2SO4, and the color developedwas read at 490 nmusing an absorbance
plate reader.
Cell Proliferation Assay
Prostate cancer cells (PC-3 and DU-145) were plated in duplicate at
a density of 50,000 cells per well in 2 ml of culture medium in six-well
plates. Cells were grown in regular medium with 10% FBS in control
and treatment (ATN-658) group. Cell growth was analyzed at two dif-
ferent doses of ATN-658 (10 and 50 μg/ml). Cells were trypsinized,
and the number of viable cells was determined using 0.4% trypan blue
and counted at different time points starting from day 1 using a Coulter
counter (model ZF; Coulter Electronics, Harpenden, Hertfordshire,
UK). Cell culture mediumwas replenished every second day along with
the indicated dose of ATN-658 in the treatment group. The experi-
ment was repeated twice.
Boyden Chamber Matrigel Invasion Assay
PC-3 and DU-145 cell invasive capacity was determined using a
two-compartment Boyden chamber Matrigel invasion assay (Transwell;
Costar Corning Corporation, Lowell, MA) as described previously
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[20]. The 8-μm pore polycarbonate filters were coated with Matrigel
(50 μg/filter). Medium containing 5 × 104 cells and ATN-658 (10
and 50 μg/ml) or control IgG was resuspended in 0.1 ml of serum-free
medium and added to the upper chamber. This was then placed on top
of the lower chamber that was prefilled with 0.8 ml of serum-free
medium supplemented with 25 μg/ml fibronectin (Sigma Aldrich,
Oakville, Ontario, Canada). The cells were allowed to invade through
the Matrigel (BD Biosciences, Mississauga, Ontario, Canada) onto
the filters for 18 hours at 37°C. After incubation, the medium was
removed, and the polycarbonate filters with invaded cells were fixed
in 2% paraformaldehyde, 0.5% glutaraldehyde (Sigma Aldrich) in
0.1 M phosphate buffer pH 7.4, at room temperature for 30 minutes.
The filters were washed twice with PBS, stained for 5 minutes with
0.5% toluidine blue, and washed again with PBS and mounted onto
glass slides. The number of cells invaded was examined under a light
microscope at a magnification of 40×. Ten random fields from each
experimental group were counted and the number of cells invaded
was calculated. The experiment was repeated three times.
Cell Migration Assay
Prostate cancer cells (PC-3 and DU-145) were grown in six-well
plates in RPMI + 10% FBS. Once the cells were 100% confluent,
the cell monolayer was mechanically scratched in the center of each
well with a sterile 1000-μl pipette tip. The medium and nonadherent
cells were aspirated, and the cells were washed with serum-free media.
Control cells were grown in RPMI + 2% FBS, and treated cells were
grown in RPMI + 2% FBS containing 10 and 50 μg/ml of ATN-658
for 24 hours where the culture medium was changed at 6 hours. Cells
were then washed three times with serum-free medium to get rid of
the nonadherent cells and debris. Cell migration was monitored at
different time points with an inverted bright field microscopy under
the 4× objective. Only cell-free area was selected, measured, and quan-
tified using Image ProPlus software and calculated as percentage cell
migration using the equation: % cell migration = [1 − (scratch area
at T x (hours)/scratch area at T0], where the T x is the respective time
point and T 0 is the time immediately after the scratch. These experi-
ments were repeated twice.
Western Blot Analysis
Prostate cancer cells (PC-3) were plated in 100-mm petri dishes (1 ×
106) and then serum-starved overnight. The following day, the cells were
treated with two doses of ATN-658 (10 and 50 μg/ml) in the presence
of 2% FBS for 24 hours. The cells were lysed with complete radio-
immunoprecipitation assay buffer, and the protein concentration was
determined. The cell lysates was electrophoresed on an SDS–polyacrylamide
gel, transferred onto a polyvinylidene difluoride membrane (Bio-Rad
Laboratories,Mississauga,Ontario,Canada) and detected using enhanced
chemiluminescence detection reagents (Perkin-Elmer Life Sciences,
Inc, Boston, MA).
In Vivo Tumor Growth in Prostate Cancer Model
Six-week-old male Balb C nu/nu mice were obtained from NCI Re-
search Resources, Frederick, MD. Before inoculation, PC-3 cells grow-
ing in serum-containing medium were washed with Hank’s balanced
buffer, trypsinized, and centrifuged at 1500 rpm for 5minutes. Cell pel-
lets (2.0 × 106) were resuspended in 200 μl of saline with 20%Matrigel.
An anesthetic cocktail of ketamine (50 mg/kg), xylazine (5 mg/kg),
and acepromazine (1 mg/kg) was injected intramuscularly, and 2.0 ×
106 cells were inoculated using a 26-gauge needle subcutaneously
(s.c.) into the right flank of anesthetizedmice. Animals were divided into
a control group, where animals were treated with mouse IgG1 (intra-
peritoneally [i.p.] 10 mg/kg, twice a week), and an experimental group,
where animals were treated with ATN-658 (i.p. 10 mg/kg, twice a
week). This dose of ATN-658 resulted in steady-state plasma levels
of 0.5 to 1 μM and exceeded the K d of ATN-658 for uPAR by 500
to 10,000×.
Both control and experimental animals were monitored at weekly
intervals for 7 weeks for tumor development and growth. Tumor vol-
ume was determined according to the formula: tumor volume = shorter
diameter2 × longer diameter / 2. Results were presented as the mean of
tumor volumes recorded from all animals within a particular cohort. At
the end of the study, animals were killed, and primary tumors were
removed. Half of the tumors were fixed in 10% buffered formalin for
immunohistochemical analysis, and the other half were snap-frozen in
liquid nitrogen.
In studies designed to evaluate the effect of ATN-658 on the out-
growth of PC-3 “metastases” in the bone, six-week-old male Fox Chase
severe combined immunodeficient (SCID) mice were obtained from
Charles River (St Constant, Quebec, Canada). Before inoculation,
PC-3 cell pellets (2 × 105 cells) were resuspended in 40 μl of saline
and injected with a 26-gauge needle into the tibia using a drilling
motion. Animals were randomized into a control group, where animals
were treated with mouse IgG (i.p. 10 mg/kg, twice a week), and an
experimental group, where animals were treated with ATN-658 (i.p.
10 mg/kg, twice a week). Mice were monitored weekly for tumor bur-
den. On week 4, digital radiography of hind limbs was done using a
Faxitron x-ray machine (Faxitron X-ray Corp, Wheeling, IL) to moni-
tor the development of skeletal lesions. At week 5, mice were killed,
and the left tibia was collected, decalcified, and fixed in formalin for
further immunohistochemical analysis. Skeletal lesions were calculated
as described by Yang et al. [21], where 0 = no lesions, 1 = minor lesions,
2 = small lesions, 3 = significant lesions with minor break of margins,
or 4 = significant lesions with major break in peripheral lesions. Radio-
logically affected tibia were fixed, decalcified, paraffin-embedded,
and subjected to histologic analysis as previously described [22]. In
all in vivo studies, eight animals were used in each group, radiologic
evidence of tumor is seen at week 3, and treatment with ATN-658
was started 1 day after tumor cell inoculation. All the experimental
animal protocols were in accordance with the McGill University Animal
Care Committee guidelines.
Immunohistochemical Analyses
Formalin-fixed, paraffin-embedded tissue blocks containing PC-3–
derived tumor tissues were sectioned at 4 μm and mounted onto posi-
tively charged glass slides for immunostaining. Sections were baked at
60°C for 20 minutes, deparaffinized through three changes of xylene,
and rehydrated through graded alcohols. After rehydration, tissue sec-
tions were incubated in 3% hydrogen peroxide for 5 minutes to quench
endogenous peroxidase, followed by antigen retrieval as indicated in
Table 1. Slides were rinsed in Splash-T Buffer (Mosaic Laboratories)
for 5 minutes and incubated with primary antibodies diluted in Dako
Antibody Diluent (Dako) for the time indicated in Table 1. Slides were
washed in three changes of Splash-T buffer for 5 minutes, and detec-
tion was performed using the Envision+ detection kit (Dako). Slides
were washed in three changes of Splash-T buffer for 5 minutes, and
color was developed using DAB (Dako) for 5 minutes. Slides were
washed in distilled water, counterstained with hematoxylin, dehydrated
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through graded alcohols, cleared through three changes of xylene, and
coverslipped.
The staining intensity for each antibody was judged relative to the
intensity of a control slide containing an adjacent section stained with
an irrelevant, negative control antibody that is species- and isotype-
matched to the test article. Staining of the section labeled with the
negative reagent control is considered “background.” A score of 0 indi-
cates no staining relative to background, 1+ indicates weak staining, 2+
indicates moderate staining, and 3+ indicates strong staining. Total
positive staining (the sum of all staining at 1+, 2+, and 3+) was recorded
for each specimen.
Statistical Analysis
Results were analyzed as the mean ± SE, and comparisons of the
experimental data were analyzed by an independent two-sample t′ test
at the P < .05 level of significance.
Results
Effect of ATN-658 on Cell Proliferation Invasion
and Migration
The ability of ATN-658 to compete 125I-scuPA binding to HeLa
cells, which express uPAR but not uPA, is shown in Figure 1A.
ATN-617 is a control antibody that is known to inhibit the binding
of uPA to uPAR. In another set of studies, the binding of biotinylated
ATN-658 directly to PC-3 cells was measured. Biotin–ATN-658
bound to these cells in a saturable manner with a K d ∼ 1 nM, similar
to the K d observed for ATN-658 binding to HeLa in the absence of
scuPA (Figure 1B).
The levels of expression of uPAR and its ligand uPA were examined
in human prostate cancer cells. Whereas uPA expression was undetect-
able in LNCaP cells, it was readily detected in both DU-145 and PC-3
cells (data not shown). The level of uPAR in PC-3 was higher than
DU-145 cells and was similar to that seen in HT1080 cells, a fibro-
sarcoma cell line described to express high levels of uPAR [23]. To
evaluate the effect of ATN-658 on prostate cancer cell doubling time,
PC-3 and DU-145 cells were treated with different doses of con-
trol IgG or ATN-658 for 5 days. Treatment with ATN-658 had no
statistically significant effect on prostate cancer cell proliferation
(Figure 1C ).
We then examined the effect of ATN-658 on PC-3 and DU-145
cells’ invasive capacity using a Matrigel Boyden chamber invasion assay.
Cells treated with ATN-658 exhibited a dose-dependent inhibition
in tumor cell invasive capacity compared with cells treated with simi-
lar dose of control IgG (Figure 1D). These effects were not due to any
change in cell proliferation during the incubation period, where ATN-
658 had no significant effect as shown in Figure 1C .
A cell migration assay was also performed. PC-3 and DU-145 cells
were treated with different doses of control IgG or ATN-658 for
24 hours. After the end of this treatment period, cells were allowed
to migrate for different periods (3, 6, and 24 hours). The highest dose
(50 μg/ml) of ATN-658 tested had a statistically significant effect on
reducing cell migration in both the uPAR expressing prostate cancer
cell lines (PC-3 and DU-145) after 24 hours (Figure 1, E and F ),
whereas no effect was observed on non–uPAR-expressing LNCaP cells
(data not shown). Throughout the course of these studies, no signifi-
cant effect on PC-3 cell morphology was observed after treating with
ATN-658 at any of the doses tested. Control IgG or a uPAR targeted
antibody (ATN-617) that inhibited uPA binding to uPAR had no ef-
fect on prostate cancer cell invasion and migration (data not shown).
Effect of ATN-658 on Intracellular Signaling Pathways
In Vitro
The interaction between uPAR and integrins results in the activation
of various intracellular signaling pathways that are known to play im-
portant roles in tumor progression. To evaluate the ability of ATN-
658 to affect these signaling pathways, PC-3 cells were treated with
50 μg/ml of control IgG or ATN-658 for 24 hours. At the end of this
incubation period, cell lysates were subjected to Western blot analysis.
Significant inhibition of phosphorylation of AKT, MAPK, and FAK
was seen in cells treated with ATN-658 (Figure 2), indicating that this
antibody had pleiotropic effects on pathways associated with uPAR-
dependent signaling.
Effect of ATN-658 on PC-3 Tumor Growth In Vivo
To test the effect of ATN-658 on tumor growth, PC-3 cells were
inoculated s.c. into the right flank of male Balb C nu/numice. Animals
were treated with 10 mg/kg of control IgG or ATN-658 twice weekly
through the i.p. route. Tumor volumes were determined at weekly in-
tervals and compared with tumor-bearing animals receiving control,
isotype-matched IgG. Experimental animals treated with ATN-658
showed a significant decrease in their tumor volume compared with
the control group of animals, which showed a progressive increase in
tumor growth throughout the course of these studies (Figure 3).
Effect of ATN-658 on PC-3 Experimental Skeletal Metastasis
In Vivo
uPAR/integrin interactions result in the activation of signaling path-
ways that are involved in skeletal biology and in the development and
Table 1. Summary of Immunohistochemistry Methods.
Antibody Source Antigen Retrieval Dilution Incubation Time (min)
Ki-67 Thermo Scientific HighTide 40 min at 95°C 1:800 30
Murine CD31 Santa Cruz Biotechnologies BORG 3 min at 125°C 1:1600 30
uPAR Attenuon DIVA 30 sec at 125°C 1:10,000 30
CC3 Cell Signaling HighTide 40 min at 95°C 1:320 30
Akt Abcam DIVA 40 min at 95°C 1:2000 120
pAkt (S473) Cell Signaling HighTide 40 min at 95°C 1:40 120
ERK Santa Cruz Biotechnologies DIVA 30 sec at 125°C 1:6400 30
pERK (T202 and Y204) Cell Signaling DIVA 3 min at 125°C 1:100 30
FAK Epitomics DIVA 3 min at 125°C 1:240 overnight
pFAK (Y397) Biosource Proteinase K 1:400 30
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Figure 1. Displacement of uPA binding by ATN-658 to PC-3 and HeLa cells and effect on prostate cancer cell proliferation, invasion, and
migration in vitro. Binding to HeLa (A) and PC-3 (B) cells was carried out in triplicate at each concentration of antibody as described in
Materials and Methods. Human prostate cancer cells PC-3 (left) and DU-145 (right) were plated in six-well plates and treated with control
IgG (CTL) or two different doses of ATN-658. Cell growth rate was determined in each group was determined after trypsinization and count-
ing the number of cells as described inMaterials andMethods (C). Results are represented asmean± SEM of duplicate wells for each time
point. Similar results were obtained in two independent experiments. PC-3 (left) and DU-145 (right) cell invasive capacity was evaluated
after treating with control IgG or ATN-658 using a Boyden chamber Matrigel invasion assay. Number of cells invading is shown as bar
diagram ± SEM (D) as described in Materials and Methods. A migration assay was carried out on PC-3 (E) and DU-145 (F) cells in the
presence of control IgG or two different doses of ATN-658 in cells culture medium containing 2% FBS as shown in panels E and F. For
these studies, cells were seeded at the same density, allowed to grow asmonolayer, and scratched as described inMaterials andMethods.
Migration at different time points was recorded, and percent migration compared with T 0 was calculated. Results are presented as the
mean ± SEM of two different experiments (lower panels of E and F). A significant difference from the control (CTL) is represented by an
asterisk (P < .05).
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progression of skeletal metastasis, a common complication in prostate
cancer patients. We therefore carried out studies to examine the effect
of ATN-658 on PC-3 cell experimental skeletal metastasis. For these
studies, PC-3 cells were inoculated directly into the tibia of male Fox
Chase SCID mice. Animals were treated with 10 mg/kg control IgG or
ATN-658 twice weekly through the i.p. route. Radiologic examination
of tibias by was carried out at weekly intervals by Faxitron. A marked
decrease in the number and area of skeletal lesions was consistently
observed in animals receiving ATN-658 compared with control animals
(Figure 4). Although ATN-658 was effective at both weeks 4 (45%)
and 5 (65%) after tumor cell inoculation, these effects were more
pronounced when treatment was administered for 5 weeks. These
antimetastatic effects of ATN-658 were also confirmed by histologic
examination of tibia from control and experimental animals (Figure 4).
Effect of ATN-658 on Intracellular Signaling Pathways,
Tumor Cell Proliferation, and Gene Expression in Primary
Tumors and Experimental Skeletal Metastasis In Vivo
At the end of each in vivo study, all control and experimental animals
were killed, and tumor-bearing tissue was removed. Primary tumor
and tibia were fixed, decalcified (tibia), and subjected to immuno-
histochemical analysis. The levels of expression of pMAPK and pFAK
in both control and ATN-658–treated tumors grown s.c. were simi-
lar. However, after treating with ATN-658, a significant reduction in
the expression of pAKTwas observed in ATN-658–treated s.c. tumors
(data not shown). In contrast to tumors grown s.c., a marked reduc-
tion in pMAPK, pFAK, and pAKTwas seen in the tumors grown in
the tibia of animals treated with ATN-658 compared with tibias from
mice receiving control IgG (Figure 5). No significant change in the
levels of expression of total MAPK, FAK, and AKTwas observed be-
tween control and experimental s.c. and intratibial (i.t.) tumors (data
not shown). Tibia from control and experimental animals were also
subjected to immunohistochemical analysis to determine the effect
on tumor cell proliferation, angiogenesis, apoptosis, and uPAR expres-
sion using antibodies targeting Ki67, cleaved caspase 3 (CC3), CD31,
and uPAR. Results from these studies showed no significant change in
the levels of expression of CD31 and CC3 after treating with ATN-658
(data not shown). In contrast, treatment with ATN-658 resulted in a
significant decrease in KI67 and uPAR expression compared with ani-
mals receiving control IgG (Figure 6).
Discussion
The therapeutic targeting of uPAR has proven to be a difficult chal-
lenge, and there are currently no uPAR-targeted therapeutic agents
being evaluated in human clinical trials. Although the system contains
several well-validated targets, only a single molecule, an enzyme in-
hibitor of uPA, has reached human clinical trials. Thus, the promise
of targeting this receptor therapeutically has not been realized and re-
mains to be explored. Studies published in the literature in recent years
have elucidated numerous activities for uPAR in addition to tethering
uPA to the cell surface. The identification of a number of ligands that
bind to uPAR in addition to uPAhas opened up the possibility that there
might exist other ways of targeting uPAR therapeutically that do not
involve inhibiting its interaction with uPA. In fact, being able to target
uPAR therapeutically while uPA is bound to uPAR is attractive from a
pharmacological standpoint since very often, a large percentage of uPAR
is already bound with endogenous uPA and agents that are intended to
displace uPA would have a higher barrier to overcome than those that
Figure 1. (continued).
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could bind to uPAR regardless of the presence of uPA. With this in
mind, a mouse monoclonal antibody (ATN-658) was identified from
a larger panel of monoclonal antibodies raised against proteolytic frag-
ments of uPAR, which did not block the binding of uPA to uPAR and
could bind to uPAR even when uPA was also bound. uPA itself can ac-
tivate several signaling pathways through binding to uPAR, but uPAR-
mediated signaling in the absence of uPA is not well understood [24].
In this study, we demonstrate that this antibody inhibits the activa-
tion of FAK, AKT, andMAPK in PC-3 cells in vitro, signaling pathways
that have previously been shown to be activated in a uPAR-dependent
manner [13,25]. Although we have not yet identified exactly which in-
teraction of uPAR is inhibited by ATN-658, we do know that this
antibody binds to domain 3 of uPAR, and studies are underway to un-
derstand how ATN-658 is functioning at the molecular level. In PC-3
cells, the functional result of inhibiting FAK, AKT, and MAPK activa-
tion in vitro is the inhibition of migration and invasion. We demon-
strate that although this inhibition can be observed in uPAR-expressing
prostate cancer cell lines (PC-3 and DU-145), these effects are more pro-
nounced in cells (PC-3) expressing high levels of uPAR. For our in vivo
studies, we focused on evaluating the effect of ATN-658 on PC-3 cell
growth in models of s.c. and i.t. growth. PC-3 cells express high levels
of uPAR, comparable to the HT1080 cell line, a well-characterized
uPAR-expressing fibrosarcoma line [22]. PC-3 cells are the best char-
acterized andmost frequently used prostate line in the i.t. model, another
reason for using this cell line in vivo. In experienced hands, the rate of
tumor take in these models can be 100%, which allows full evaluation
of the efficacy of potential therapeutic agents as shown in the current
study. It should be noted that, in models of pancreatic [18] and colon
cancer [25], inhibition of proliferation by ATN-658 has also been ob-
served albeit only in vivo. In the current PC-3 study, ATN-658 also
Figure 2. Inhibition of tyrosine phosphorylation of signaling intermediates by ATN-658. PC-3 cells were treatedwith 50.0 μg/ml of control IgG
(CTL) or ATN-658 for 24 hours. Cells were harvested, and 40 μg of total cellular protein was subjected toWestern blot analysis as described
in Materials and Methods using antibodies against AKT, phosphorylated (p) AKT, MAPK, pMAPK, FAK, and pFAK. Anti–β-tubulin antibody
was used as loading control. Levels of expression of these proteins were determined by densitometric scanning and represented as rela-
tive density. Results are presented as the mean ± SEM of two different experiments. A significant difference from the control (CTL) is
represented by an asterisk (P < .05).
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inhibits tumor growth in vivo both when cells are inoculated s.c. as well as
when they are inoculated i.t. in amodel that we believe represents prostate
cancer metastasis outgrowth in the bone. Although the inhibition of tu-
mor growth is statistically significant when the tumors are grown s.c., the
magnitude of inhibition by ATN-658 seems greater in the i.t. model. An
analysis of the activation of FAK, AKT, and MAPK reveals that only
MAPK activation is inhibited in the tumors grown s.c., whereas the ac-
tivation of all three signaling effectors is impaired in the i.t. models. This
difference in these effects on signaling may be one explanation of why
ATN-658 seems to be more effective in the i.t. model. The reason for
this difference between the models where the tumors are inoculated in
different anatomic locations is unknown, although a simple explanation
(and one hypothesis) is that the difference is due to the different pharma-
cology of drug delivery and tumor perfusion rather than a mechanistic
explanation. For example, tumor perfusion by ATN-658 may be differ-
ent when the tumor is grown s.c. compared with that in the bone (bone
being highly vascularized to begin with and therefore more amenable to
drug delivery of a macromolecule), and we have previously observed
differences in the antitumor activity of ATN-658 depending on whether
treatment was initiated when a tumor was small or large (with a greater
magnitude of antitumor activity observed against larger established tu-
mors, consistent with differences in the ability of ATN-658 to perfuse
a tumor) [26]. Alternatively, the differences on signaling and tumor
growthmay bemanifestations of differences in tumormicroenvironment.
For example, uPARmay engage a different set of binding partners in bone
tumors compared with s.c. tumors that lead to the observed differences
in the effects on signaling depending on the anatomic location of the
tumor. It is well known clinically that tumors of the same so-called
histologic subtype (e.g., prostate cancer) behave differently depending
on the histologic location, exposure to previous treatments, and so on,
and in fact, a “prostate cancer” in bone is really a different disease than
prostate cancer in the prostate [27]. As an extension of these clinical ob-
servations, it is interesting to observe that in the i.t. model, ATN-658
seems to have greater efficacy with prolonged treatment. Unfortunately,
it is difficult to extend thismodel longer than the 5-week period presented
in this study to see if the increase in antitumor activity would continue
because of the morbidity associated with the PC-3 lesions in the tibia of
control animals once the mice pass the 5-week point. What is known is
that ATN-658 does not affect the interaction of uPAR with vitronectin
(VN) and does not bind to the epitope on uPAR that interacts with VN
so it is unlikely that the antitumor effects of ATN-658 are mediated
through altering the interaction of VN with uPAR. We have recently
published the crystal structure of the VN-uPAR complex, and the epi-
tope of ATN-658 has recently been described [28,29].
ATN-658 does not bind to mouse uPAR. In addition, although
ATN-658 is a monoclonal antibody, it is an IgG1 isotype that does
not mediate antibody-directed cytotoxicity in mice (this has been con-
firmed in vitro using mouse effector and tumor cells; data not shown).
Figure 3. Effect of ATN-658 on prostate cancer growth in vivo. Male
Balb C nu/numice were inoculated with (2 × 106) PC-3 cells through
the s.c. route. Animals were treated with 10.0 mg/kg of control
IgG (CTL) or ATN-658 through the i.p. route. Tumors were mea-
sured weekly, and tumor volume was determined as described in
Materials andMethods. Result represents the mean ± SEM of eight
animals in each group. Significant differences from control are repre-
sented by asterisks (P < .05).
Figure 4. Effect of ATN-658 on prostate cancer skeletal lesions
in vivo. Male Fox Chase SCID mice were inoculated with (2 × 106)
PC-3 cells through the i.t. route. Animals were treated with 10.0 mg/
kg of control IgG (CTL) or ATN-658 through the i.p. route. Devel-
opment of skeletal lesions was determined at weekly intervals by
x-ray using Faxitron, and lesion area was determined as described
in Materials and Methods. Skeletal lesions in radiographs are high-
lighted by arrows, and histologic analysis was carried by hema-
toxylin and eosin (H&E) staining where i.t. tumors are marked as
“T”. Representative radiograph lesion score of control and experi-
mental animals at weeks 4 and 5 after tumor cell inoculation is shown
in lower panels. Result represents the mean ± SEM of eight animals
in each group. Significant differences from control are represented
by asterisks (P < .05).
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Thus, the antitumor effects that are observed in this study are likely
due to the antagonistic effects of ATN-658 against the human uPAR
expressed by the implanted PC-3 tumor cells. Using immunohisto-
chemical analysis of i.t. tumors, no effects of ATN-658 on apoptosis
were observed using CC3 as a marker. In addition and not surprisingly
given the lack of ATN-658’s ability to bind to host-derived uPAR, no
effects were observed on angiogenesis using CD31 immunostaining
(data not shown). In contrast, ATN-658 strongly inhibited tumor cell
proliferation (Figure 6), consistent with a previous study evaluating
ATN-658 in a model of pancreatic carcinoma, and also led to the
down-regulation of uPAR expression on the tumor cells [18]. In addi-
tion, despite the fact that uPAR is expressed on PC-3 cells in culture,
some of these cells lose uPAR expression when grown in vivo because
uPAR does not seem to expressed by all cells within a PC-3 tumor even
in nontreated controls (Figure 6). Thus, the apparent antitumor activity
of ATN-658 may be dampened in vivo if the expression of uPAR is, for
some reason, lost in some of the tumor cells. The loss of uPAR expres-
sion by the PC-3 cells in vivo is currently not understood but could be
attributable to a number of reasons that contribute to tumor hetero-
geneity including differences in the interaction with the tumor micro-
environment that might occur in different parts of the tumor and
differences in tumor oxygenation. In humans, we would predict that
this antibody would have the potential for even greater antitumor ac-
tivity than that observed in these mouse models because in addition to
tumor cells per se, the antibody would also target uPAR expressed on
angiogenic endothelium and tumor-associated infiltrating cells such as
neutrophils and macrophages, both of which can contribute to tumor
progression [30]. In cancer patients, soluble uPAR (suPAR) may also be
present and may be relevant to disease progression. For example, suPAR
has been demonstrated to be associated with poor prognosis in patients
with ovarian cancer [31]. One concern is that high levels of suPARmay
alter the activity of ATN-658 by acting as a sink for the antibody and
sequestering its availability from delivery to the tumor. As described in
the Results, we are able to achieve micromolar steady-state concentrations
Figure 5. ATN-658 inhibits the expression of signaling molecules in prostate cancer tumors and skeletal lesions in vivo. Male Fox chase
SCID mice were inoculated with PC-3 cells through the i.t. route of injection, respectively. Animals were treated with 10.0 mg/kg of control
IgG (CTL) or ATN-658. At the end of these studies, animals were killed, and tibias were removed, formalin-fixed, and subjected to immuno-
histochemical analysis as described inMaterials andMethods. Result represents themean± SEMof five tibias from each group. Significant
differences from control are represented by asterisks (P < .05).
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of ATN-658, whereas the levels of suPAR in cancer patients are on
the order of nanograms per milliliter (fM). Thus, little or no effect of
suPAR on ATN-658 plasma levels is predicted. ATN-658 has now
been humanized and is currently in late-stage preclinical development.
Despite the fact that a number of questions remain regarding the mecha-
nism of action of how ATN-658 exerts its antitumor effects at the mo-
lecular level, there is a sufficient body of basic evidence that supports
advancing the humanized version of ATN-658 into clinical evaluation.
In addition, the bulk of Investigational New Drug Application–enabling
studies have already been completed, and thus, the humanized version
of ATN-658 (huATN-658) is expected to imminently enter a phase 1
clinical study. Thus, the hypothesis that uPAR represents a validated
tumor target in human cancer and that therapeutically targeting this
receptor will have clinical benefit in cancer patients will begin evalua-
tion in the near future.
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